Vaxxinity Inc, a pharmaceutical company based in the United States, is dedicated to revolutionizing healthcare worldwide. With a focus on ESG principles, Vaxxinity is developing synthetic peptide-based medicines to transform the treatment of chronic diseases. By harnessing innovative technology, the company aims to make healthcare more accessible and efficient, offering new hope for patients with conditions such as Alzheimer's, Parkinson's, migraine, and hypercholesterolemia. With a medium-risk ESG score of 29.9, Vaxxinity is at the forefront of creating sustainable solutions for global health challenges.